CD163 and breast cancer: In accordance with this, using an independent dataset (GEO accession number GSE202203) comprising primary tumor GEX from 3207 patients with early breast cancer [20], high levels of CD163 GEX (quartiles 1–3 versus quartile 4) associated with shorter relapse-free survival and overall survival (P = 0.009 and P = 0.00007, respectively; Supplemental Fig. 3).